Claiming Compensation for Incorrect Dose Content Statement in Flutiform Inhaler Recall

A recall of Flutiform 250 micrograms / 10 micrograms per actuation pressurised inhalation suspension by CD Pharma Ltd has highlighted a labelling error. This issue reportedly revolves around an incorrect dose content statement on the outer carton of specific batches, as notified to the MHRA.

The Group Action Lawyers specialises in helping affected individuals pursue compensation through group actions when pharmaceutical errors like this occur. This article explores the details of the recall and how people might be eligible to generally claim compensation in such circumstances.

Understanding the Incorrect Dose Content Statement Issue

The core problem in this Class 2 Medicines Recall is reportedly the incorrect dose content statement printed on the packaging. According to the official notification from the MHRA, the delivered dose content statement mistakenly lists “approximately 115 micrograms of fluticasone propionate and 4.5 micrograms of formoterol fumarate dihydrate,” whereas the correct figures should be “approximately 230 micrograms of fluticasone propionate and 9 micrograms of formoterol fumarate dihydrate.”

This error is understood to affect batches including 270185-24062FA-30424, 270186-24065FA-30443, 270774-24082FB-30444, and 269881-24064FA-30425, all with expiry dates in 2026 and distributed starting from late June 2025.

Whilst the MHRA emphasises that the medicine’s quality remains unaffected and patients should continue use as prescribed, the incorrect dose content statement could lead to confusion among some users and healthcare professionals. Such discrepancies in labelling might contribute to misuse or anxiety.

Impact on Patients and Healthcare Providers

Patients using Flutiform for asthma or COPD management may have encountered this labelling flaw without realising its implications. The recall advises quarantining and returning affected stock at the wholesale and pharmacy level, but for those who already possess the product, the advice is to proceed with treatment whilst reporting any adverse reactions via the MHRA Yellow Card scheme.

From a legal standpoint, errors like an incorrect dose content statement can erode trust in pharmaceutical products and may entitle affected parties to seek redress. If you have suffered side effects, financial losses from replacing medication, or emotional distress due to such issues, joining a group action could amplify your voice and increase the chances of a successful claim against the responsible parties.

How Group Actions Work for Pharmaceutical Matters

Group actions, also known as class actions, can allow multiple claimants to band together against a common defendant, such as a pharmaceutical company, for issues stemming from product defects. In cases involving labelling errors, compensation might cover medical expenses, lost wages, or pain and suffering, depending on individual circumstances.

The Group Action Lawyers has handled numerous medical cases, ensuring that victims of negligence receive fair settlements. This recall, published on 24 July 2025 by the MHRA, underscores the need for accountability, and we are investigating potential claims related to it.

If you have been affected by a recall and any associated incorrect dose content statement, do not delay—contact The Group Action Lawyers today for a free, no-obligation consultation.

Our experts can assess your eligibility for a group action claim and guide you through the process. Call us at 0800 634 7575 or visit our website to start your claim now and secure the compensation you deserve.